IMO this is the real money quote:
"The implications to the results of the trial are broad reaching and create a tremendous opportunity for our infectious disease division"
This trial confirms the potential of Defensin mimetics. Brilacidin is just the tip of the iceberg.
It is a revolutionary drug: new family of pharmaceuticals, no resistance , single dose efficacy, no serious side effects. Plus we hold the patents to Brilacidin and its analogues.
How many potential drugs can be developed in this new family of drugs? CTIX has reported it is studying defensin mimetics for fungal infections, tuberculosis, malaria. Studies will be performed for every infection known including: viruses, parasites, protozoa, prions.
If there is no resistance then there will be no objections to developing the huge veternarian and ag market
Plus CTIX has hinted at its noninflammatory properties.
FDA expediated review should be expected.
Major Pharma partners should be lining up.
all IMO Farrell
News 
Market Data 
Discover 
